Cargando…
2403. Comparison of Daptomycin Combination Therapy With Ceftaroline or Oxacillin Against Methicillin-Resistant Staphylococcus aureus (MRSA) Isolates Causing Persistent Bacteremia
BACKGROUND: Increasing evidence suggests that daptomycin (DAP) demonstrates in vitro synergy in combination with other anti-staphylococcal agents, including ceftaroline (CPT) and oxacillin (OXA), against MRSA. Nevertheless, optimal combinations remain undefined. Here, our objective was to compare DA...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254037/ http://dx.doi.org/10.1093/ofid/ofy210.2056 |
_version_ | 1783373632030900224 |
---|---|
author | Bouchard, Jeannette Jones, Chelsea Kline, Ellen Oleksiuk, Louise-Marie Shields, Ryan K |
author_facet | Bouchard, Jeannette Jones, Chelsea Kline, Ellen Oleksiuk, Louise-Marie Shields, Ryan K |
author_sort | Bouchard, Jeannette |
collection | PubMed |
description | BACKGROUND: Increasing evidence suggests that daptomycin (DAP) demonstrates in vitro synergy in combination with other anti-staphylococcal agents, including ceftaroline (CPT) and oxacillin (OXA), against MRSA. Nevertheless, optimal combinations remain undefined. Here, our objective was to compare DAP in combination with CPT or OXA against MRSA bloodstream isolates collected from patients with persistent bacteremia despite >7 days of vancomycin treatment. METHODS: Minimum inhibitory concentrations (MICs) for DAP, CPT, and OXA were determined in duplicate by reference broth microdilution methods. We used time-kill analyses (TKA) to test free peak concentrations (fC(max)) of DAP (8 µg/mL), CPT (16 µg/mL), and OXA (4 µg/mL) alone and in combination against 1 × 10(8) CFU/mL to simulate high-inocula infections. Bactericidal and synergistic activity were defined as a ≥3-log(10) decrease in CFU/mL and >2-log(10) decrease in CFU/mL in combination compared with the most active single agent, respectively, at 24 hours. RESULTS: A representative isolate was selected from 12 patients with persistent MRSA bacteremia. Median (range) MICs were 0.5 (0.5–1), 0.5 (0.5–1), and 64 (64–≥128) µg/mL for DAP, CPT, and OXA, respectively. By TKA (n = 5 isolates), median log-kills were −3.81, −1.90, and +1.99 log(10)CFU/mL for DAP, CPT, OXA, respectively. Corresponding rates of bactericidal activity were 80%, 20%, and 0%, respectively. In combination, median log-kills were −7.83 and −4.82 log(10)CFU/mL for DAP+CPT and DAP+OXA, respectively (P = 0.111; Figure 1). DAP was synergistic in combination with CPT or OXA against 80% and 60% of isolates, respectively. Median log-kills in combination with CPT or OXA were higher than DAP alone (P = 0.003 and P = 0.0497, respectively). At 24 hours, colony counts were below the lower limit of detection (50 CFU/mL) against 60% and 20% of isolates exposed to DAP+CPT or DAP+OXA, respectively. CONCLUSION: Among persistent MRSA bloodstream isolates, combinations of DAP + CPT or OXA demonstrates synergy and statistically greater killing effects in vitro at fCmax concentrations than DAP alone. Log-kills were greatest with DAP+CPT, which merits further validation in pre-clinical models. [Image: see text] DISCLOSURES: All authors: No reported disclosures. |
format | Online Article Text |
id | pubmed-6254037 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-62540372018-11-28 2403. Comparison of Daptomycin Combination Therapy With Ceftaroline or Oxacillin Against Methicillin-Resistant Staphylococcus aureus (MRSA) Isolates Causing Persistent Bacteremia Bouchard, Jeannette Jones, Chelsea Kline, Ellen Oleksiuk, Louise-Marie Shields, Ryan K Open Forum Infect Dis Abstracts BACKGROUND: Increasing evidence suggests that daptomycin (DAP) demonstrates in vitro synergy in combination with other anti-staphylococcal agents, including ceftaroline (CPT) and oxacillin (OXA), against MRSA. Nevertheless, optimal combinations remain undefined. Here, our objective was to compare DAP in combination with CPT or OXA against MRSA bloodstream isolates collected from patients with persistent bacteremia despite >7 days of vancomycin treatment. METHODS: Minimum inhibitory concentrations (MICs) for DAP, CPT, and OXA were determined in duplicate by reference broth microdilution methods. We used time-kill analyses (TKA) to test free peak concentrations (fC(max)) of DAP (8 µg/mL), CPT (16 µg/mL), and OXA (4 µg/mL) alone and in combination against 1 × 10(8) CFU/mL to simulate high-inocula infections. Bactericidal and synergistic activity were defined as a ≥3-log(10) decrease in CFU/mL and >2-log(10) decrease in CFU/mL in combination compared with the most active single agent, respectively, at 24 hours. RESULTS: A representative isolate was selected from 12 patients with persistent MRSA bacteremia. Median (range) MICs were 0.5 (0.5–1), 0.5 (0.5–1), and 64 (64–≥128) µg/mL for DAP, CPT, and OXA, respectively. By TKA (n = 5 isolates), median log-kills were −3.81, −1.90, and +1.99 log(10)CFU/mL for DAP, CPT, OXA, respectively. Corresponding rates of bactericidal activity were 80%, 20%, and 0%, respectively. In combination, median log-kills were −7.83 and −4.82 log(10)CFU/mL for DAP+CPT and DAP+OXA, respectively (P = 0.111; Figure 1). DAP was synergistic in combination with CPT or OXA against 80% and 60% of isolates, respectively. Median log-kills in combination with CPT or OXA were higher than DAP alone (P = 0.003 and P = 0.0497, respectively). At 24 hours, colony counts were below the lower limit of detection (50 CFU/mL) against 60% and 20% of isolates exposed to DAP+CPT or DAP+OXA, respectively. CONCLUSION: Among persistent MRSA bloodstream isolates, combinations of DAP + CPT or OXA demonstrates synergy and statistically greater killing effects in vitro at fCmax concentrations than DAP alone. Log-kills were greatest with DAP+CPT, which merits further validation in pre-clinical models. [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2018-11-26 /pmc/articles/PMC6254037/ http://dx.doi.org/10.1093/ofid/ofy210.2056 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Bouchard, Jeannette Jones, Chelsea Kline, Ellen Oleksiuk, Louise-Marie Shields, Ryan K 2403. Comparison of Daptomycin Combination Therapy With Ceftaroline or Oxacillin Against Methicillin-Resistant Staphylococcus aureus (MRSA) Isolates Causing Persistent Bacteremia |
title | 2403. Comparison of Daptomycin Combination Therapy With Ceftaroline or Oxacillin Against Methicillin-Resistant Staphylococcus aureus (MRSA) Isolates Causing Persistent Bacteremia |
title_full | 2403. Comparison of Daptomycin Combination Therapy With Ceftaroline or Oxacillin Against Methicillin-Resistant Staphylococcus aureus (MRSA) Isolates Causing Persistent Bacteremia |
title_fullStr | 2403. Comparison of Daptomycin Combination Therapy With Ceftaroline or Oxacillin Against Methicillin-Resistant Staphylococcus aureus (MRSA) Isolates Causing Persistent Bacteremia |
title_full_unstemmed | 2403. Comparison of Daptomycin Combination Therapy With Ceftaroline or Oxacillin Against Methicillin-Resistant Staphylococcus aureus (MRSA) Isolates Causing Persistent Bacteremia |
title_short | 2403. Comparison of Daptomycin Combination Therapy With Ceftaroline or Oxacillin Against Methicillin-Resistant Staphylococcus aureus (MRSA) Isolates Causing Persistent Bacteremia |
title_sort | 2403. comparison of daptomycin combination therapy with ceftaroline or oxacillin against methicillin-resistant staphylococcus aureus (mrsa) isolates causing persistent bacteremia |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254037/ http://dx.doi.org/10.1093/ofid/ofy210.2056 |
work_keys_str_mv | AT bouchardjeannette 2403comparisonofdaptomycincombinationtherapywithceftarolineoroxacillinagainstmethicillinresistantstaphylococcusaureusmrsaisolatescausingpersistentbacteremia AT joneschelsea 2403comparisonofdaptomycincombinationtherapywithceftarolineoroxacillinagainstmethicillinresistantstaphylococcusaureusmrsaisolatescausingpersistentbacteremia AT klineellen 2403comparisonofdaptomycincombinationtherapywithceftarolineoroxacillinagainstmethicillinresistantstaphylococcusaureusmrsaisolatescausingpersistentbacteremia AT oleksiuklouisemarie 2403comparisonofdaptomycincombinationtherapywithceftarolineoroxacillinagainstmethicillinresistantstaphylococcusaureusmrsaisolatescausingpersistentbacteremia AT shieldsryank 2403comparisonofdaptomycincombinationtherapywithceftarolineoroxacillinagainstmethicillinresistantstaphylococcusaureusmrsaisolatescausingpersistentbacteremia |